Compare ACLS & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLS | FOLD |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.5B |
| IPO Year | 2000 | 2006 |
| Metric | ACLS | FOLD |
|---|---|---|
| Price | $166.66 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $101.50 | $27.25 |
| AVG Volume (30 Days) | 785.7K | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $839,048,000.00 | N/A |
| Revenue This Year | $1.93 | $20.50 |
| Revenue Next Year | $7.91 | $18.59 |
| P/E Ratio | $42.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $55.96 | $5.66 |
| 52 Week High | $171.61 | $14.50 |
| Indicator | ACLS | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 74.29 | 74.18 |
| Support Level | $77.19 | $14.21 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 8.30 | 0.02 |
| MACD | 1.97 | -0.00 |
| Stochastic Oscillator | 89.42 | 100.00 |
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.